34 Patents
- US126124622026Treatment and Inhibition of Inflammatory Lung Diseases in Patients Having Risk Alleles in the Genes Encoding IL33 and IL1RL1
Regeneron Pharmaceuticals, Inc.
0 cites - US125841742026Treatment of Psoriasis with Interferon Induced Helicase C Domain 1 (IFIH1) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US125775622026Treatment of Glaucoma with Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US124722412025Treatment of Respiratory Disorders with Arachidonate 15-lipoxygenase (ALOX15) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US123702572025Materials and Methods of Treating Mhc-i-opathy Risk Haplotypes
Regeneron Pharmaceuticals, Inc.
0 cites - US12359201202517ß-hydroxysteroid Dehydrogenase Type 13 (HSD17B13) Irna Compositions and Methods of Use Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US122866772025Inhibition of HSD17B13 in the Treatment of Liver Disease in Patients Expressing the PNPLA3 I148M Variation
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US122586272025Kelch Domain Containing 7B (KLHDC7B) Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US122344602025Methods of Treating Decreased Bone Mineral Density with Cluster of Differentiation 109 (CD109) Inhibitors
The Royal Institution For The Advancement Of Learning/mcgill University
0 cites - US122153222025Treatment of Liver Disease with Mitochondrial Glycerol-3-phosphate Acyltransferase (GPAM) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US121863782025Methods of Treating Skin Cancer with Histidine Ammonia-lyase (HAL) Agonists
Regeneron Pharmaceuticals, Inc.
0 cites - US121631922024Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US121578912024Treatment of Uveitis with Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US121230012024Methods of Treating Liver Diseases with Phosphodiesterase 3B (PDE3B) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US120704602024Methods of Treating Skin Cancer with Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US120182592024Treatment of Liver Diseases with Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US119577042024Methods of Treating Metabolic Disorders and Cardiovascular Disease with Inhibin Subunit Beta E (INHBE) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US119396352024Treatment of Obesity in Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)
Regeneron Pharmaceuticals, Inc.
0 cites - US118916072024Methods of Treating Decreased Bone Mineral Density with Cluster of Differentiation 109 (CD109) Inhibitors
The Royal Institution For The Advancement Of Learning/mcgill University
0 cites - US118651342024Treatment of Inflammation with Glucocorticoids and Angiopoietin-like 7 (ANGPTL7) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US118459892023Treatment of Ophthalmic Conditions with Angiopoietin-like 7 (ANGPTL7) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US118209822023Treatment of Ophthalmic Conditions with Son of Sevenless 2 (SOS2) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US117733932023Treatment of Liver Diseases with Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US117675262023Treatment of Ophthalmic Conditions with Angiopoietin-like 7 (ANGPTL7) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - US117594762023Methods of Treating Metabolic Disorders and Cardiovascular Disease with Inhibin Subunit Beta E (INHBE) Inhibitors
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US117521972023Macrophage Stimulating 1 Receptor (MST1R) Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US117084152023Treatment and Inhibition of Inflammatory Lung Diseases in Patients Having Risk Alleles in the Genes Encoding IL33 and IL1RL1
Regeneron Pharmaceuticals, Inc.
0 cites - US117027002023Inhibition of HSD17B13 in the Treatment of Liver Disease in Patients Expressing the PNPLA3 I148M Variation
Regeneron Pharmaceuticals, Inc.
0 cites - US116741772023Kelch Domain Containing 7B (KLHDC7B) Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US115849662023Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Variants and Uses Thereof
Regeneran Pharmaceuticals, Inc.
0 cites